{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:19:44Z","timestamp":1789564784139,"version":"build-2803163510"},"reference-count":41,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"\n Importance<\/jats:title>\n \n Stereotactic ablative radiotherapy (SABR) is used for treating lung tumors but can cause toxic effects, including life-threatening damage to central structures. Retrospective data suggested that small tumors up to 10 cm\n 3<\/jats:sup>\n in volume can be well controlled with a biologically effective dose less than 100 Gy.\n <\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess whether individualizing lung SABR dose and fractionation by tumor size, location, and histological characteristics may be associated with local tumor control.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This nonrandomized controlled trial (the iSABR trial, so named for individualized SABR) was a phase 2 multicenter trial enrolling participants from November 15, 2011, to December 5, 2018, at academic medical centers in the US and Japan. Data were analyzed from December 9, 2020, to May 10, 2023. Patients were enrolled in 3 groups according to cancer type: initial diagnosis of non\u2013small cell lung cancer (NSCLC) with an American Joint Committee on Cancer 7th edition T1-3N0M0 tumor (group 1), a T1-3N0M0 new primary NSCLC with a history of prior NSCLC or multiple NSCLCs (group 2), or lung metastases from NSCLC or another solid tumor (group 3).<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n \n Up to 4 tumors were treated with once-daily SABR. The dose ranged from 25 Gy in 1 fraction for peripheral tumors with a volume of 0 to 10 cm\n 3<\/jats:sup>\n to 60 Gy in 8 fractions for central tumors with a volume greater than 30 cm\n 3<\/jats:sup>\n .\n <\/jats:p>\n <\/jats:sec>\n \n Main outcome<\/jats:title>\n Per-group freedom from local recurrence (same-lobe recurrence) at 1 year, with censoring at time of distant recurrence, death, or loss to follow-up.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n In total, 217 unique patients (median [IQR] age, 72 [64-80] years; 129 [59%] male; 150 [69%] current or former smokers) were enrolled (some multiple times). There were 240 treatment courses: 79 in group 1, 82 in group 2, and 79 in group 3. A total of 285 tumors (211 [74%] peripheral and 74 [26%] central) were treated. The most common dose was 25 Gy in 1 fraction (158 tumors). The median (range) follow-up period was 33 (2-109) months, and the median overall survival was 59 (95% CI, 49-82) months. Freedom from local recurrence at 1 year was 97% (90% CI, 91%-99%) for group 1, 94% (90% CI, 87%-97%) for group 2, and 96% (90% CI, 89%-98%) for group 3. Freedom from local recurrence at 5 years ranged from 83% to 93% in the 3 groups. The proportion of patients with grade 3 to 5 toxic effects was low, at 5% (including a single patient [1%] with grade 5 toxic effects).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The results of this nonrandomized controlled trial suggest that individualized SABR (iSABR) used to treat lung tumors may allow minimization of treatment dose and is associated with excellent local control. Individualized dosing should be considered for use in future trials.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT01463423<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoncol.2023.3495","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T11:18:48Z","timestamp":1694690328000},"page":"1525","source":"Crossref","is-referenced-by-count":29,"title":["Individualized Stereotactic Ablative Radiotherapy for Lung Tumors"],"prefix":"10.1001","volume":"9","author":[{"given":"Michael F.","family":"Gensheimer","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet","family":"Gee","sequence":"additional","affiliation":[{"name":"Sydney West Radiation Oncology Network, Sydney, New South Wales, Australia"},{"name":"University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Shirato","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Faculty of Medicine, Hokkaido University, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Taguchi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Faculty of Medicine, Hokkaido University, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Snyder","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander L.","family":"Chin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas K.","family":"Vitzthum","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Maxim","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California Irvine, Irvine, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather A.","family":"Wakelee","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Neal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Millie","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel T.","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Kidd","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven L.","family":"Hancock","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Shultz","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen C.","family":"Horst","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quynh-Thu","family":"Le","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngan","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Billy W.","family":"Loo","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Diehn","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"coi230045r1","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/S1470-2045(18)30896-9","article-title":"Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non\u2013small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.","volume":"20","author":"Ball","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"coi230045r2","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/S1470-2045(15)70168-3","article-title":"Stereotactic ablative radiotherapy versus lobectomy for operable stage I non\u2013small-cell lung cancer: a pooled analysis of two randomised trials.","volume":"16","author":"Chang","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"coi230045r3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.radonc.2016.08.015","article-title":"SPACE\u2014a randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC.","volume":"121","author":"Nyman","year":"2016","journal-title":"Radiother Oncol"},{"key":"coi230045r4","doi-asserted-by":"publisher","author":"Siva","DOI":"10.1001\/jamaoncol.2021.2939"},{"issue":"5","key":"coi230045r5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.prro.2017.04.014","article-title":"Stereotactic body radiation therapy for early-stage non\u2013small cell lung cancer: executive summary of an ASTRO evidence-based guideline.","volume":"7","author":"Videtic","year":"2017","journal-title":"Pract Radiat Oncol"},{"issue":"1","key":"coi230045r6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.radonc.2017.05.012","article-title":"ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non\u2013small cell lung cancer.","volume":"124","author":"Guckenberger","year":"2017","journal-title":"Radiother Oncol"},{"issue":"11","key":"coi230045r8","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1001\/jama.2010.261","article-title":"Stereotactic body radiation therapy for inoperable early stage lung cancer.","volume":"303","author":"Timmerman","year":"2010","journal-title":"JAMA"},{"issue":"30","key":"coi230045r9","doi-asserted-by":"publisher","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","article-title":"Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer.","volume":"24","author":"Timmerman","year":"2006","journal-title":"J Clin Oncol"},{"issue":"15","key":"coi230045r10","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1200\/JCO.18.00622","article-title":"Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non\u2013small-cell lung cancer: NRG Oncology\/RTOG 0813 Trial.","volume":"37","author":"Bezjak","year":"2019","journal-title":"J Clin Oncol"},{"issue":"7","key":"coi230045r11","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1097\/JTO.0b013e318074de34","article-title":"Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non\u2013small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study.","volume":"2","author":"Onishi","year":"2007","journal-title":"J Thorac Oncol"},{"issue":"1","key":"coi230045r12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ijrobp.2008.06.1939","article-title":"Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation.","volume":"74","author":"Guckenberger","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"coi230045r13","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1097\/JTO.0b013e3182614bf3","article-title":"Stereotactic body radiotherapy for central lung tumors.","volume":"7","author":"Rowe","year":"2012","journal-title":"J Thorac Oncol"},{"issue":"10","key":"coi230045r14","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1200\/JCO.2008.19.6386","article-title":"Multi-institutional phase I\/II trial of stereotactic body radiation therapy for lung metastases.","volume":"27","author":"Rusthoven","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"coi230045r15","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.ijrobp.2018.11.051","article-title":"Long-term follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): a randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non\u2013small cell lung cancer.","volume":"103","author":"Videtic","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"coi230045r16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.ijrobp.2010.04.070","article-title":"Stereotactic ablative radiotherapy should be combined with a hypoxic cell radiosensitizer.","volume":"78","author":"Brown","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"coi230045r17","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.ijrobp.2020.03.005","article-title":"Correlating dose variables with local tumor control in stereotactic body radiation therapy for early-stage non\u2013small cell lung cancer: a modeling study on 1500 individual treatments.","volume":"107","author":"Klement","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"coi230045r18","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ijrobp.2019.03.045","article-title":"Local control after stereotactic body radiation therapy for stage I non\u2013small cell lung cancer.","volume":"110","author":"Lee","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"coi230045r19","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1097\/01243894-200610000-00008","article-title":"Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors.","volume":"1","author":"Le","year":"2006","journal-title":"J Thorac Oncol"},{"issue":"1","key":"coi230045r20","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ijrobp.2011.10.071","article-title":"Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors.","volume":"84","author":"Trakul","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"coi230045r21","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.ijrobp.2017.02.093","article-title":"Stereotactic ablative radiation therapy for pulmonary metastases: histology, dose, and indication matter.","volume":"98","author":"Helou","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"coi230045r22","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.ijrobp.2015.04.004","article-title":"Colorectal histology is associated with an increased risk of local failure in lung metastases treated with stereotactic ablative radiation therapy.","volume":"92","author":"Binkley","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"coi230045r23","doi-asserted-by":"publisher","article-title":"Motion management and image guidance for thoracic tumor radiotherapy: clinical treatment programs","author":"Loo","DOI":"10.1159\/issn.0071-9676"},{"issue":"6","key":"coi230045r24","doi-asserted-by":"publisher","first-page":"e607","DOI":"10.1016\/j.prro.2015.05.008","article-title":"Anatomic optimization of lung tumor stereotactic ablative radiation therapy.","volume":"5","author":"Yu","year":"2015","journal-title":"Pract Radiat Oncol"},{"issue":"9","key":"coi230045r25","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1001\/jamaoncol.2018.1258","article-title":"Long-term results of stereotactic body radiation therapy in medically inoperable stage I non\u2013small cell lung cancer.","volume":"4","author":"Timmerman","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"coi230045r26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.lungcan.2015.04.014","article-title":"Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors.","volume":"89","author":"Chaudhuri","year":"2015","journal-title":"Lung Cancer"},{"issue":"6","key":"coi230045r27","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1097\/JTO.0000000000000525","article-title":"Stereotactic body radiotherapy using a radiobiology-based regimen for stage I non\u2013small-cell lung cancer: five-year mature results.","volume":"10","author":"Shibamoto","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"2","key":"coi230045r28","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0360-3016(99)00507-6","article-title":"Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05.","volume":"47","author":"Shaw","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"coi230045r29","doi-asserted-by":"publisher","journal-title":"Int J Radiat Oncol Biol Phys","DOI":"10.1016\/j.ijrobp.2022.09.002"},{"issue":"1","key":"coi230045r30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ijrobp.2019.02.047","article-title":"Biological principles of stereotactic body radiation therapy (SBRT) and stereotactic radiation surgery (SRS): indirect cell death.","volume":"110","author":"Song","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"coi230045r31","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.ijrobp.2019.08.019","article-title":"One versus three fractions of stereotactic body radiation therapy for peripheral stage I to II non\u2013small cell lung cancer: a randomized, multi-institution, phase 2 trial.","volume":"105","author":"Singh","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"coi230045r32","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.jtho.2016.11.002","article-title":"A Histologic basis for the efficacy of SBRT to the lung.","volume":"12","author":"Woody","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"3","key":"coi230045r33","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jtho.2020.11.015","article-title":"Clinical implications of KEAP1-NFE2L2 mutations in NSCLC.","volume":"16","author":"Hellyer","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"1","key":"coi230045r34","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1158\/2159-8290.CD-16-0127","article-title":"Role of KEAP1\/NRF2 and tp53 mutations in lung squamous cell carcinoma development and radiation resistance.","volume":"7","author":"Jeong","year":"2017","journal-title":"Cancer Discov"},{"issue":"6","key":"coi230045r35","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/ng.3564","article-title":"Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas.","volume":"48","author":"Campbell","year":"2016","journal-title":"Nat Genet"},{"issue":"12","key":"coi230045r36","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1158\/2159-8290.CD-20-0282","article-title":"KEAP1\/NFE2L2 Mutations predict lung cancer radiation resistance that can be targeted by glutaminase inhibition.","volume":"10","author":"Binkley","year":"2020","journal-title":"Cancer Discov"},{"issue":"8","key":"coi230045r37","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.jtho.2019.04.018","article-title":"Safety and effectiveness of stereotactic ablative radiotherapy for ultra-central lung lesions: a systematic review.","volume":"14","author":"Chen","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"7","key":"coi230045r38","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.jtho.2021.03.019","article-title":"The HILUS-trial: a prospective Nordic multicenter phase 2 study of ultracentral lung tumors treated with stereotactic body radiotherapy.","volume":"16","author":"Lindberg","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"8","key":"coi230045r39","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/S1470-2045(12)70242-5","article-title":"Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non\u2013small-cell lung cancer: a retrospective analysis.","volume":"13","author":"Senthi","year":"2012","journal-title":"Lancet Oncol"},{"issue":"3","key":"coi230045r40","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.cllc.2015.09.006","article-title":"Recurrence patterns and second primary lung cancers after stereotactic body radiation therapy for early-stage non\u2013small-cell lung cancer: implications for surveillance.","volume":"17","author":"Spratt","year":"2016","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"coi230045r41","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ijrobp.2021.11.027","article-title":"A systematic review into the radiologic features predicting local recurrence after stereotactic ablative body radiotherapy (SABR) in patients with non\u2013small cell lung cancer (NSCLC).","volume":"113","author":"Lee","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"coi230045r7","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology non\u2013small cell lung cancer version 1.2022. Accessed February 22, 2022 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2809582\/jamaoncology_gensheimer_2023_oi_230045_1699901590.83102.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T11:06:06Z","timestamp":1700132766000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2809582"}},"subtitle":["The iSABR Phase 2 Nonrandomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2023.3495","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,1]]}}}